Securities Class Action Filed Against Gildan Activewear

What happened

On October 19, 2026, Rosen Law Firm announced a class action lawsuit on behalf of Gildan Activewear Inc. (GIL) investors who purchased shares between February 19, 2025 and June 15, 2026. The suit, first filed by the firm, comes after a sharp decline in Gildan's share price in June 2026 following short-seller allegations of channel stuffing and revenue quality concerns. While the specific claims in the lawsuit are not detailed in the announcement, the class period aligns with the period during which Gildan completed its HanesBrands acquisition and subsequently faced scrutiny over inventory management and distributor sell-in practices. The lawsuit adds legal and reputational risk to an already challenged investment thesis that hinges on proving clean growth and restoring credibility. Investors should monitor case developments as they could influence both sentiment and incremental costs.

Implication

The lawsuit does not immediately alter Gildan's fundamental self-help story—synergy capture, Australia divestiture, and free cash flow generation remain intact—but it increases uncertainty and potential legal expenses. Given the stock's recent 27% decline and already depressed valuation metrics, the market may partly price in litigation risk, but the credibility discount is unlikely to narrow until the case progresses and quarterly results confirm clean growth. Investors should reduce position size if they hold the stock above $44 (near base-case value) and resist adding until either the stock approaches the $36 attractive entry or evidence of channel normalization and legal resolution emerges. The core thesis hinges on Q3 2026 revenue and receivables quality; the lawsuit is a secondary but real risk that could pressure management's attention and financials. Maintain a wait-and-see approach, with a bias to trim on rallies rather than chase.

Thesis delta

The class action does not change Gildan's operating thesis but adds a legal overhang that reinforces the existing WAIT rating. The fundamental drivers—synergy execution, debt reduction via Australia sale, and revenue-quality proof—remain unchanged, but the lawsuit increases downside tail risk and extends the timeline for credibility restoration. Entry attractiveness may improve only if the stock falls to $36 or if the lawsuit is dismissed or settled with minimal financial impact.